All Māhele

Kahua>Products>ʻO nā huahana Pharmaceutical i hoʻopau>Cardiovascular & Urinary

Tranexamic Acid Injection


Hoʻoponopono Kūmole:

2ml: 0.2g

10 amps / pahu


Kākoʻo OEM/ODM:ʻAe

MOQ:500,000 Nā Kauaka

Delivery Time:30 ~ 55 Nā lā

Kūʻai Term:FOB, CIF

Palena Palena:T / T, L / C

Loaʻa maʻamau:CP,BP

palapala:GMP, CPP, FSC, CTD



1. This product is primarily used for all types of bleeding due to acute or chronic, limited or systemic primary fibrinolysis. It is generally not used in secondary hyperfibrinolytic states caused by disseminated intravascular coagulation prior to heparinization.

2. For trauma or surgical bleeding in fibrinogen-rich organs such as prostate, urethra, lung, brain, uterus, adrenal gland and thyroid.

3. Used as an antagonist of tissue-type fibrinogen activator (t-PA), streptokinase and urokinase.

4. For fibrinolytic bleeding due to miscarriage, early placental abruption, stillbirth and amniotic fluid embolism, and increased menorrhagia due to localized fibrinolytic lesions in the uterine cavity.


Nā hana'ino

1. Occasionally, there is intracranial thrombosis and bleeding due to drug overdose.

2.There may be diarrhea, nausea, and vomiting.

3.Less commonly, there is menstrual discomfort (due to blood clotting during menstruation).4 Because the product can enter the cerebrospinal fluid, central nervous system symptoms such as blurred vision, headache, dizziness, and fatigue may occur after injection, especially in relation to the rate of injection, but are rare.





E mālama i kahi maloʻo, maloʻo a pouli.

E mālama i nā lāʻau a pau mai nā keiki.